



A Prospective Study on Side Effect Profile in Helicobacter Pylori Positive Patients Taking Standard Triple Therapy

Limi Joseph Gomez¹, Arathi S Nair ¹, Aleena Francis¹, Bushra Abdul Rahim¹, Soumya R V^{2*} and Prasobh G R³

¹Doctor of Pharmacy Interns, ²Assistant Professor and ³Principal, Sree Krishna College of Pharmacy and Research Centre, Parassala, Trivandrum, Kerala, India.

Received: 14 Jul 2020/ Accepted: 16 Aug 2020 / Published online: 01 Oct 2020

*Corresponding Author Email: tosoumyarv@gmail.com

Abstract

Helicobacter pylori eradication fails in 10% of patients particularly due to occurrence of drug resistance and side effects. **AIM:** The objective of the research is to monitor the side effect and on tolerability of standard triple therapy to eradicate *H. pylori*. **METHODOLOGY:** A prospective observational study was carried out in the gastroenterology department for which Rapid Urease test was carried out in patients with abdominal symptom as chief complaint and 90 *H. pylori* positive patients were recruited for this study. The side effects were assessed using *de Bore et al.* questionnaire, which was provided during first and second week. In order to evaluate the impact of side effects on treatment compliance, tolerability was assessed using a 5-point scale. **RESULT AND DISCUSSION:** The result was analyzed using paired T test. On analyzing the tolerability, no discomfort was observed in 32 patients (36.4%) during the first week which was increased to 38 (43.3%) at the second week. Slight discomfort has been reported in about 52.3% (46 patients) and 50% (44 patients) in the first and second week. Moderate discomforts were seen in 11.3% (10 patients) and 6.81% (6 patients) after completion. Among all these categories bitter taste was the most common side effect. The most severe side effect which may result in discontinuation of therapy was diarrhea, whose incidence was reduced by the addition of probiotics thrice daily. **CONCLUSION:** Thus, it was concluded as early identification of side effect can reduce the incidence of drug discontinuation and decrease drug resistance.

Keywords

Helicobacter Pylori, Standard Triple Therapy, Rapid Urease Test, Side effect.

INTRODUCTION:

Helicobacter pylori (*H.pylori*) is a Gram-negative bacterium that selectively colonizes the gastric epithelium. *H. pylori* infection is closely associated with the incidence of gastrointestinal diseases ^[1, 2]. In some developing countries, the prevalence of *H. pylori* is about 80–90% ^[3]. If left untreated it may

cause chronic gastritis, and extra gastric manifestations such as vitamin B12 deficiency, thrombocytopenia purpura. ^[4]

Current treatment guidelines recommend Standard Triple therapy, combining a proton-pump inhibitor (PPI) with Amoxicillin and Clarithromycin is the mainstay of treatment. ^[5] Clarithromycin is the most

effective single agent against *H. pylori* in vivo^[6] has additive antibacterial activity with its metabolite as well as amoxicillin.^[7] This action is due to decrease in pH gradient across the mucus layer and to change the pharmacokinetic properties of amoxicillin and clarithromycin in the stomach.^[8,9]

But its eradication rate has been declined due to the antibiotic resistance and poor patient compliance caused by side effects of traditional regimen such as diarrhea, nausea, vomiting etc.^[10, 11, 12]. Various other factors in the failure of *H. pylori* eradication are included poor diet, a high bacterial load of the gastric, internalization of bacteria, gastric acidity, gene polymorphisms, antimicrobial washout, and most importantly, antibiotic resistance.^[13]

Antibiotic associated side effect is a major drawback involving complex regimens in *H. pylori* eradication^[14]. About 20-25% of people experience side effect that can result in cessation of treatment and thus causing failure of eradication. Gastrointestinal side effects may be due to reduction in normal flora or overgrowth of potentially pathogenic antibiotic resistant strains.^[15, 16] In regions with high resistance to clarithromycin, treatment with four drugs including bismuth subsalicylate, PPI, tetracycline, and metronidazole are recommended as primary therapies.^[17]

Since medication compliance has been considered the most important factor in *H. pylori* eradication, a major goal is aimed at early identification of side effects so as improving the compliance thus indirectly decrease the eradication rate and antibiotic resistance.

MATERIALS AND METHODS:

A prospective observational study was carried out in the gastroenterology department of a territory care hospital. The duration of the study was six months. Upper GI endoscopy and Rapid Urease test was carried out in 90 patients with abdominal symptom as their chief complaint and *H. pylori* positive patients were recruited for this study. Written informed consent was obtained as per ICMR biomedical research guideline from patients diagnosed as *Helicobacter pylori* positive satisfying the inclusion and exclusion criteria. All information relevant for the study will be collected from case records and by

directly interviewing the patients. The selected subjects were provided with Standard Triple therapy containing Amoxicillin, Proton pump inhibitor and Clarithromycin for a period of 14 days

Inclusion Criteria

- Patients on standard Triple therapy for *Helicobacter pylori*
- Patients of age 18-80 years.
- Patients with positive rapid urease test (RUT).

Exclusion Criteria

- Patients with previous history of *Helicobacter pylori* eradication.
- Patients with hepatic and renal impairment.
- Pregnant and lactating women.
- Patients on prolonged proton pump inhibitors, antibiotics therapy, anticoagulants and NSAIDS.
- Patients who have a history of allergy or hypersensitivity to any antibiotics in the regimen.

Side effect profile and treatment tolerability were assessed in each patient using de Boer et al. questionnaire. Often the uncertainty in defining a symptom as a side effect make it extremely difficult to compare side effect profile, to avoid this de Boer et al. questionnaire was administered twice during the study, after the first and second week of treatment course, respectively. In order to obtain the highest compliance patient were provided careful instructions and training. The questionnaire contains two parts in which the first one is tolerability which was assessed using a five-point scale. This consist of no side effect, slight discomfort, moderate discomfort, severe discomfort but continued the treatment and severe discomfort hence forced to discontinue. The second part involves assessing side effects like taste disturbance, loss of appetite, nausea, diarrhea headache etc. which was asked to justify based on severity

For data entry we had used the software Microsoft excel and all the analysis were carried out with the help of statistical software SPSS v.22 version for WINDOWS.

The side effects during and after the treatment was statistically assessed using paired T test. A calculated p-value less than 0.05 considered to be statistically significant.

RESULTS

Background characteristics of the patient were collected, and the results are demonstrated in Chart 1




Chart 1 Age Distribution

The gender distribution is demonstrated in Chart 2. Out of the total patients enrolled in the study, the prevalence of *H.pylori* infection was higher in males i.e. 50/88 (56.8%) compared to females i.e. 38/88

(43.2%). It was estimated that majority of these male patients consumed food from outside on a regular basis.

GENDER DISTRIBUTION




Chart 2 Gender Distribution

The tolerability of standard triple therapy is demonstrated in Chart 3. The side effects were categorized as mild, moderate, and severe based on the interference, with the daily activities.

Out of the total patients 32 (36.4%) can well tolerate the regimen at the first week and 38(43.3%) were at second week. Slight discomfort of side effects being reported about 52.3% (46 patients) in the first week and 50% (44/88) in the second week (Chart 3).




Chart 3 Tolerability to Standard Triple Therapy

After completion of regimen moderate discomfort of side effects seen in 10 patients at the first week and 6 patients at the second week

Side effects of Triple therapy is demonstrated in Table 1. Most reported side effect is bitter taste (41.1%) in both first and second week followed by

nausea (15.5%), Loss of appetite and diarrhea (8.9%). The incidence of adverse effects like nausea, diarrhea, epigastric pain was mitigated through the addition of probiotics mainly *Saccharomyces boulardii* thrice daily for patients with moderate to severe side effect. (figure1 & 2)

Table 1. Side effect profile of Standard triple therapy

Side effects	First week				Second week			
	None	Mild	Moderate	Severe	None	Mild	Moderate	Severe
Bitter taste	38	13	25	12	38	21	20	9
Nausea	74	9	4	1	76	10	1	1
Diarrhoea	82	2	2	2	87	1	0	0
Vomiting	87	1	0	0	88	0	0	0
Headache	84	3	1	0	87	1	0	0
LOA	81	4	3	0	83	3	2	0
Stomach pain	85	2	1	0	87	1	0	0




Figure 1: Diagrammatic representation of distribution of side effects in first week




Figure 2: Diagrammatic representation of distribution of side effects in second week

The incidence of adverse effects such as bitter taste (p-value ≤ 0.011), nausea (p-value ≤ 0.041), diarrhea (p-value ≤ 0.027), vomiting (p-value ≤ 0.032), headache (p-value ≤ 0.01), loss of appetite (p-value ≤ 0.038), and abdominal pain (p-value ≤ 0.018) was reduced significantly in the second week

DISCUSSION:

The study describes the tolerability and side effects of standard triple therapy in H. Pylori patients.

For the cure of any disease the appropriate medications must be provided to obtain effective outcomes. H. pylori infection is one among the most common gastrointestinal infections. Because of the increasing rate of drug resistance and lack of absolute superior antibiotics, eradication research focuses on all kind of regimens.^[18,19] Several therapies are available for H. pylori eradication.^[20] The standard triple therapy is the first line treatment for H. pylori which consists of proton pump inhibitors (PPI), clarithromycin and amoxicillin. The treatment course ranges from 10days to 2 weeks.^[21, 22]

Since the therapy include combination regimen the occurrence of side effects is higher. Moreover, macrolide antibiotics, such as clarithromycin, have been related to increased contractility of gastrointestinal smooth muscle, which may lead to increased motility and accelerated transit with diarrhea.^[23] However, there is difficulty in differentiating a symptom from a side effect. Additionally, because of such discrepancies, the frequencies of side-effects in many triple therapy studies have a broad range, but the severity of manifestations is described as 'mild' to 'moderate'.^[24-27]

There were some relevant gastrointestinal side effects observed during the eradication. Side effect profile and treatment tolerability were assessed in

each patient using de Boer et al. questionnaire.^[28]

This is regarded as the most accurate proposed, because it planned as a mix of previously adopted questionnaires.^[28-30]

In most studies frequency and severity of side effects of the treatment are poorly described for standard first-line triple therapy the overall rate of adverse events was 53.3% in a multicenter study by Misiewicz et al. and these were rarely serious with only one patient experiencing pseudomembranous colitis.^[31] The most frequently reported adverse events in their study was diarrhea, headache, and taste disturbance which was similar to our study in which the most common were taste disturbance, nausea and diarrhea.

However, J. C. Thijs et al. found only acceptable incidence of side effects may be since patients were already about possible side effects before starting treatment could have influenced the results negatively.^[32] Although the incidence of the individual side effects was rather high, they were generally very mild. Practically all patients completed the prescribed treatment, and more than 80% had no or just minor side effects.

In contrast another study by Lind T et al found that high incidence of adverse effects with triple therapy (33%) when compared with other regimens and among them the most common adverse effect was loose stools and taste perversion.^[33] He also concluded that incidence of gastrointestinal side effects were more with addition of amoxicillin which will be the reason for highest rate of side effects with triple therapy when compared with other regimens containing metronidazole. He also specifies that taste disturbance is more with regimens containing clarithromycin that could be the result of highest prevalence of taste disturbance and diarrhea in this study.^[34]

The data regarding the side effects of Standard Triple Therapy shows that 43.2% of patients were able to tolerate the therapy without any side effects. The most common side effects experienced were mild nausea, bitter taste and diarrhea. In this study the most common reported side effect was bitter taste which has the potential to cause discontinuation of therapy. This study aims to identify the side effects early and provide appropriate measure to avoid discontinuation that may increase the risk of drug resistance and disease reappearance.

For those patients with moderate to severe side effect that can even lead to stoppage of therapy supplementation of probiotic was useful. A probiotic is defined as a 'live microbial organism which, when ingested, beneficially affects human health, including amelioration or prevention of a specific disease state'.^[35] Most probiotics are deemed to colonize the human gut, and certain species, such as *Lactobacillus* spp., can colonize the human stomach, directly or indirectly antagonizing *H. pylori*.^[36-40] This effect can prevent or decrease the incidence of antibiotic associated side effects

CONCLUSION:

The study was conducted to assess the tolerability and side effect of Standard Triple Therapy. The study was conducted using 90 patients who were RUT positive. The patients after being recruited were provided with regimen containing Amoxicillin (1000mg), Clarithromycin (500mg), and Proton Pump Inhibitor twice daily. 36.4% and 43.2% patients were able to tolerate the therapy without any side effects during the first and second week and out of the 88 patients 52.3% and 50% patients' experienced mild side effects like bitter taste, nausea, and diarrhea. Mostly reported side effect is bitter taste (41.1%) in both first and second week followed by nausea (15.5%), Loss of appetite and diarrhoea (8.9%). The incidence of adverse effects like nausea, diarrhoea, epigastric pain was mitigated through the addition of probiotics.

Early identification of side effects can reduce the incidence of drug discontinuation and decrease drug resistance. Furthermore, the reduction in antibiotic-associated side effects such as nausea, vomiting, diarrhea, and epigastric pain improves medication tolerance and patient compliance.

ACKNOWLEDGEMENTS:

Authors would like to thank Dr. Unnikrishnan L.S., Honorable Senior Consultant, Department of Gastroenterology who helped us in collecting the data for this study

CONFLICT OF INTEREST:

Conflict of interest declared none.

REFERENCES:

- Chen C, Mao Y, Du J, Xu Y, Zhu Z, Cao H. *Helicobacter pylori* infection associated with an increased risk of colorectal adenomatous polyps in the Chinese population. BMC Gastroenterol. 2019; 19 (1): 14.
- Wang F, Meng W, Wang B, Qiao L. *Helicobacter pylori*-induced gastric inflammation and gastric cancer. Cancer Lett. 2014; 345 (2): 196–202.
- Jarosz M, Rychlik E, Siuba M, Respondek W, Ryzko-Skiba M, Sajor I, et al. Dietary and socio-economic factors in relation to *Helicobacter pylori* re-infection. World J Gastroenterol. 2009; 15 (9): 1119–25.
- Barkun A, et al. Systematic review of the symptom burden, quality-of-life impairment, and costs associated with peptic ulcer disease. Am J Med 2010; 123(4):358–66.
- Chey, William D, Leontiadis, Grigorios I, Howden, Colin W, Moss, Steven F, ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection, American Journal of Gastroenterology: February 2017 - Volume 112 - Issue 2 - p 212-239.
- Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of *Helicobacter pylori*: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860–4.
- Cederbrandt G, Kahlmeter G, Schalen C, Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against *Helicobacter pylori*. J Antimicrob Chemother 1994; 34: 1025–9.
- Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of antibiotics in gastric juice. Gastroenterology 1995; 106: A102.
- Gustavson LE, Kaiser JF, Mukherjee DX, DeBartolo M, Schneck DW. Evaluation of pharmacokinetic drug interactions between clarithromycin (C) and omeprazole (O). Am J Gastroenterol 1994; 89: 1373.
- Deltenre M, Ntounda R, Jonas C, De Koster E. Eradication of *Helicobacter pylori*: why does it fail? Ital J Gastroenterol Hepatol 1998; 30(Suppl. 3): S326-8.
- Graham DY, Borsch GMA. The who's and when's of therapy for *Helicobacter pylori*. Am J Gastroenterol 1990; 85: 1552-5.
- Graham DY, Lew GM, Maltby HM, et al. Factors influencing the eradication of *Helicobacter pylori* with triple therapy. Gastroenterology 1992;102:493-6.
- A.M.H. Afsahi, A. Ebrahimi, Z. Amini, D. Esmaeili, Evaluation of the effect of *Lactobacillus planetarium* probiotics produced from broad bean seed in prevention of *Helicobacter pylori* in stomach tissue of C57BL/6 mice, J. Cancer Sci. Ther. 10 (4) (2018) 85–89.
- De Boer WA, Tytgat GNJ. The best therapy for *Helicobacter pylori* infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995; 30: 401-7

15. Nord CE, Heimdal A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. *Scand J Infect Dis* 1986; 49: 64-72.
16. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxicillin, plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in *Helicobacter pylori*-infected patients. *J Antimicrob Chemother* 1999; 44: 629-40.
17. M. Safavi, R. Sabourian, A. Foroumadi, Treatment of *Helicobacter pylori* infection: current and future insights, *World J. Clin. Cases* 4 (1) (2016) 5–19.
18. Gaspretto M, Pescarin M, Guariso G. *Helicobacter* eradication therapy: current availabilities. *ISRN gastroenterol* 2012; 2012: 186734.
19. Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I et al. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin and amoxicillin in the treatment of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 2011; 23:865-70
20. Randel A. H. *pylori* Infection: ACG Updates Treatment Recommendations. *Am Fam Physician*. 2018; 97(2): 135-137.
21. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for eradication. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD008337. DOI: 10.1002/14651858.CD008337.pub2
22. Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of *Helicobacter pylori* infection--the Maastricht Consensus Report. The European *Helicobacter Pylori* Study Group (EHPG). *Eur J Gastroenterol Hepatol*. 1997 Jan. 9(1):1-2
23. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. *Drugs* 1992; 44: 117–64.
24. Harris A. Current regimens for treatment of *Helicobacter pylori* infection. *Br Med Bull* 1998; 54: 195-205
25. Penston JG, McColl KEL. Eradication of *Helicobacter pylori*: an objective assessment of current therapies. *Br J Clin Pharmacol* 1997; 43: 223-43.
26. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2000; 14: 79-83.
27. Cammarota G, Cannizzaro O, Ojetti V, et al. Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxicillin or tinidazole for *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2000; 14: 73-7
28. De Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain CO, Tytgat GNJ. Proposal for use of a standard side effect scoring system in studies exploring *Helicobacter pylori* treatment regimens. *Eur J Gastroenterol Hepatol* 1996; 8: 641-3.
29. De Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Effect of acid suppression on efficacy of treatment for *Helicobacter pylori* infection. *Lancet* 1995; 345: 817-20.
30. Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating *Helicobacter pylori*. *Gut* 1995; 37: 477-81.
31. Misiewicz, J.J., Harris, A.W., Bardham, K.D., Levi, S., O'Morain C.A., Cooper, B.T. et al. (1997) One week triple therapy for *Helicobacter pylori*: a multicentre comparative study. *Gut* 41: 735-739.
32. Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of *Helicobacter pylori*. *Scand J Gastroenterol*. 1993; 28(11):934-938.
33. Lind T, Mégraud F, Unger P, et al. The MACH2 study: role of omeprazole in eradication of *Helicobacter pylori* with 1-week triple therapies. *Gastroenterology*. 1999; 116(2):248-253.
34. Lind T, Veldhuyzen van Zanten S, Unger P, Spiller R, Bayerdorffer E, O'Morain C, Bardhan KD, et al. Eradication of *Helicobacter pylori* using one-week triple therapies combining omeprazole with two antimicrobials: the MACH1 study. *Helicobacter* 1996; 1:138–144.
35. Fuller R. Probiotics in human medicine. *Ann Med* 1990; 22:37-41
36. Armuzzi, A., Cremonini, F., Bartolozzi, F., Canducci, F., Candelli, M., Ojetti, V., G. et al. The effect of oral administration of *Lactobacillus GG* on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. *Alimentary Pharmacology & Therapeutics*, 15: 163-169.
37. Francavilla R., Lionetti E., Castellaneta S.P., Magistà A.M., Maurogiovanni G., Bucci N., et al. Inhibition of *Helicobacter pylori* infection in humans by *Lactobacillus reuteri* ATCC 55730 and effect on eradication therapy: A pilot study. *Helicobacter*. 2008; 13:127–134.
38. Ryan K.A., Jayaraman T., Daly P., Canchaya C., Curran S., Fang F., Quigley E.M., O'Toole P.W. Isolation of lactobacilli with probiotic properties from the human stomach. *Lett. Appl. Microbiol*. 2008; 47:269–274.
39. Espinoza J.L., Matsumoto A., Tanaka H., Matsumura I. Gastric microbiota: An emerging player in *Helicobacter pylori*-induced gastric malignancies. *Cancer Lett*. 2018; 414:147–152.
40. Gong, Yi et al. "Probiotics improve efficacy and tolerability of triple therapy to eradicate *Helicobacter pylori*: a meta-analysis of randomized controlled trials." *International journal of clinical and experimental medicine* vol. 8, 4 6530-43. 15 Apr. 2015.